QUOIN PHARMACEUTICALS, LTD.

(QNRX)
  Report
Delayed Nasdaq  -  05/23 04:00:00 pm EDT
0.6500 USD   +3.19%
08:31aQuoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
AQ
05/06Ladenburg Thalmann Starts Quoin Pharmaceuticals at Buy With $2 Price Target
MT
04/25Quoin Says FDA Clears Investigational New Drug Application for Netherton Syndrome Candidate
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
0.711(c) 0.67(c) 0.6501(c) 0.6299(c) 0.65 Last
158 036 97 851 104 032 46 189 62 265 Volume
+12.64% -5.77% -2.97% -3.11% +3.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -12,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,33x
Yield 2022 -
Sales 2023 0,27 M - -
Net income 2023 -10,8 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,65x
Yield 2023 -
Capitalization 5,28 M 5,28 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 19,8x
Nbr of Employees 4
Free-Float 0,24%
More Financials
Company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton... 
More about the company
Ratings of Quoin Pharmaceuticals, Ltd.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about QUOIN PHARMACEUTICALS, LTD.
08:31aQuoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment wit..
AQ
05/06Ladenburg Thalmann Starts Quoin Pharmaceuticals at Buy With $2 Price Target
MT
04/25Quoin Says FDA Clears Investigational New Drug Application for Netherton Syndrome Candi..
MT
04/25Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Ne..
AQ
04/25Quoin Pharmaceuticals, Ltd. Announces FDA Clearance of IND for its Lead Asset, QRX003, ..
CI
04/14Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 3..
CI
03/15Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Nethe..
AQ
03/15Quoin Pharmaceuticals Announces Submission of IND for Its Lead Asset, QRX003, for Nethe..
CI
03/10Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead A..
AQ
03/08QUOIN PHARMACEUTICALS : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APR..
PU
03/01Quoin Pharma Extends Distribution Deal With Partner ER-Kim for Skin Disease Drug Candid..
MT
03/01Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead..
AQ
03/01Quoin Pharmaceuticals, Inc. Extends Exclusive Distribution Agreement with ER-Kim for it..
CI
02/17Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead..
AQ
02/17Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for Its Lead..
CI
More news
News in other languages on QUOIN PHARMACEUTICALS, LTD.
04/25Quoin dit que la FDA approuve la demande de nouveau médicament de recherche pour le can..
04/25Quoin Pharmaceuticals, Ltd. annonce l'approbation par la FDA de la demande d'autorisati..
04/14Quoin Pharmaceuticals, Ltd. annonce ses résultats pour l'année complète se terminant le..
03/15Quoin Pharmaceuticals annonce la soumission d'une demande de DNR pour son actif princip..
03/01Quoin Pharma prolonge son accord de distribution avec son partenaire ER-Kim pour un can..
More news
Analyst Recommendations on QUOIN PHARMACEUTICALS, LTD.
More recommendations
Chart QUOIN PHARMACEUTICALS, LTD.
Duration : Period :
Quoin Pharmaceuticals, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUOIN PHARMACEUTICALS, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,63 $
Average target price 4,91 $
Spread / Average Target 680%
EPS Revisions
Managers and Directors
Michael Myers Chairman & Chief Executive Officer
Gordon B. Dunn Chief Financial Officer
Denise Carter Chief Operating Officer & Director
Dennis H. Langer Independent Director
Natalie Leong Independent Director
Sector and Competitors
1st jan.Capi. (M$)
QUOIN PHARMACEUTICALS, LTD.-65.39%5
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567